Navigation Links
Pharmasset to Present at Susquehanna's Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
Date:2/27/2008

PRINCETON, N.J., Feb. 27 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at Susquehanna Financial Group's Second Annual SIGnificant Investment Options in Healthcare Conference being held March 4-5, 2008 at the W Hotel in New York, NY. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company on Wednesday, March 5, 2008 from 2:00 PM to 2:30 PM (ET) in the W Hotel's Sea/Ocean Room. In addition, Dr. Michelle Berrey, Pharmasset's Chief Medical Officer, and Dr. Michael Otto, Pharmasset's Chief Scientific Officer, will participate in a hepatitis C virus (HCV) therapeutic workshop, entitled "HCV: Polymerase Inhibitors" on Wednesday, March 5, 2008 from 9:15 AM to 10:15 AM (ET).

To access a simultaneous webcast of Mr. Price's overview of the company via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: +1 (609) 613-4125


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
9. Avicena Group to Present at Noble Financial Conference
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Mass. , Jan. 18, 2017 ... applying mechanistic modeling to drug research and development, ... PhD, Co-Founder, President, and CEO of Applied BioMath, ... for Informatics and Modeling (BAGIM) Meeting on Thursday ... Cambridge , MA.   Dr. Burke,s ...
(Date:1/18/2017)... ... 2017 , ... Whitehouse Labs has furthered its efforts towards ... (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has more ... 2017. Extractable & Leachable evaluations have become increasingly more vital to successful product ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... Summit for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join ... clinical research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, ...
(Date:1/18/2017)... Shareholder rights law firm Johnson & Weaver, ... members of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD ... proposed sale of the Company to Eli Lilly and ... molecules for the acute treatment of migraines. ... a definitive merger agreement with Eli Lilly. Under the ...
Breaking Biology Technology:
(Date:1/13/2017)... , Jan. 13, 2017 Sandata Technologies, ... for the homecare industry, including Electronic Visit Verificationā„¢ ... expert, Justin Jugs, as Senior Vice President of ... 15 years of homecare experience to Sandata, where ... strategic plans to align Sandata,s suite of solutions ...
(Date:1/12/2017)... Oregon and PUNE, India , January 12, 2017 /PRNewswire/ ... Market: Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology market ... of 19.4% from 2016 to 2022. Continue Reading ... ... ...
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
Breaking Biology News(10 mins):